Developer docs
API playgroundTry for free, no card

Search company profiles

METAFORA biosystems

Full company profile

uuid0003jdk

Namestring
METAFORA biosystems
Legal namestring
METAFORA biosystems
Company typeenum
Private
Founded yearint
2011
Descriptiontext

METAFORA biosystems is a France-headquartered biotechnology company developing proprietary Receptor Binding Domain (RBD) ligands — described as innovative, unmatched ligands of nutrient transporters — and applying them to two product lines. Its core research-use platform, METAflow, delivers AI-powered cytometry and cell metabolism profiling for researchers analyzing cellular metabolic data, while METAglut1™ is a clinical diagnostic and monitoring tool for Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS). Both products are anchored on the same underlying chemistry: RBD ligands that bind specific nutrient transporters and report on cellular metabolic state through cytometry readouts enhanced by machine learning-based predictive analytics.

The company operates commercially through a direct, digital-first go-to-market: it sells via its corporate website with a "BUY NOW" option for kits and provides access to METAflow through a dedicated online portal (eu.metaflow.bio / v2.metaflow.bio), and characterizes its revenue model as subscription/recurring. Customer acquisition leans on scientific publications, webinars, and conference participation aimed at healthcare and research institutions in Western Europe and North America. METAFORA biosystems is a privately held firm founded in 2011, with its registered headquarters at the Pépinière Paris Biotech Santé incubator in Paris (29 rue du Faubourg Saint Jacques) and a US subsidiary, METAFORA biosystems, Inc., in Chicago, Illinois.

METAFORA's funding history is exclusively non-dilutive to date: an early EISMEA grant in 2017, a Horizon 2020 award of approximately $3.8M in 2018, and a European Innovation Council round of approximately $2.6M in 2022, bringing cumulative disclosed funding to roughly $6.4M. Leadership consists of co-founder Vincent Petit (CEO) and co-founder Luc d'Auriol (Chairman). The firm employs between 11 and 50 people, has no disclosed patents, partnerships, named customers, or revenue figures in the source data, and currently markets no standalone AI models, SDKs, or APIs beyond its platform portal.

Short descriptiontext

METAFORA biosystems is a French biotech that uses proprietary RBD ligands of nutrient transporters to power METAflow, an AI-enabled cytometry platform for cell metabolism research, and METAglut1™, a diagnostic for Glut1 Deficiency Syndrome, sold to research and clinical institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell metabolism profiling, AI-powered cytometry, metabolic disorder diagnostics, flow cytometry platform, nutrient transporter ligands
Industry3 codes
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI-Powered Cytometry and Cell Metabolism Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Products and Platform Services
TypeSubscription Recurring
Description

Revenue generated from sale of METAglut1 diagnostic products and METAflow platform access

metafora-biosystems.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1METAflow
Description

Flow cytometry platform for AI-powered cell metabolism analysis.

metafora-biosystems.com
+1 more record
Core offering1 text field

METAFORA biosystems develops and commercializes AI-powered cytometry and cell metabolism profiling tools built on proprietary RBD ligands of nutrient transporters. Its portfolio includes METAflow, a research-oriented cytometry platform for cell metabolism analysis, and METAglut1™, a clinical diagnostic and monitoring solution for Glut1 Deficiency Syndrome (Glut1DS). Both offerings target healthcare and research institutions globally.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

METAFORA biosystems offers a dual-product portfolio focused on AI-powered cell metabolism analysis. The core offerings include METAflow, an AI-powered cytometry and cell metabolism profiling platform, and METAglut1™, a diagnostic tool for Glut1 deficiency syndrome. Both products leverage artificial intelligence to analyze cellular metabolic data for research and clinical applications.

Product and service2 records
1METAflow
CategoryAI-Powered Cytometry / Cell Metabolism Profiling Platform
Description

METAflow is an AI-powered cytometry and cell metabolism profiling platform that enables researchers and clinical users to analyze cellular metabolic data at single-cell resolution using proprietary RBD ligands of nutrient transporters.

2METAglut1™
CategoryMetabolic Disorder Diagnostic Tool
Description

METAglut1™ is a medical diagnostic and monitoring tool for Glut1 Deficiency Syndrome (Glut1DS) that measures glucose transporter 1 deficiency through cell metabolism analysis using METAFORA's proprietary RBD ligand technology.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major flow cytometry and cell analysis incumbent (part of Danaher). Comparable to METAFORA because it serves the same research and clinical cytometry market, but with vastly broader instrument portfolios and a hardware-led model rather than METAFORA's niche metabolism-profiling AI software angle.

TypeBroad incumbent
Description

Division of Becton Dickinson and a leading flow cytometry, cell sorting, and reagent provider. Comparable to METAFORA as a flow-cytometry platform competitor targeting similar research and clinical customers, with far greater scale and a broad instrument-plus-reagent portfolio.

TypeDirect peer
Description

Specialist flow cytometry instrumentation company whose spectral cell analyzers compete for the same research-customer budgets as METAFORA's METAflow platform. Highly comparable in core technology (flow cytometry) and customer base (research institutions), though Cytek is focused on hardware while METAFORA is focused on AI-driven metabolism profiling.

TypeDirect peer
Description

Provider of mass cytometry (CyTOF) and single-cell analysis instruments used in immunology and cell metabolism research. Comparable to METAFORA because it targets the same research-customer need — deep cellular phenotyping — using cytometry-based instrumentation.

TypeBroad incumbent
Description

Single-cell and spatial omics platform company serving biomedical researchers. Comparable to METAFORA because researchers evaluating METAflow for cell metabolism profiling are often the same buyers evaluating 10x's single-cell solutions, putting them in overlapping purchasing conversations at research institutions.

TypeBroad incumbent
Description

Diversified life sciences tools giant with a deep cell-analysis portfolio (Attune, flow cytometers, reagents). Comparable as a competing supplier of flow cytometry instruments, reagents, and software to the same healthcare and research institutions METAFORA targets.

TypeEmerging player
Description

Metabolomics services and biomarker discovery company serving pharma and research customers. Comparable to METAFORA because it competes for the same "cell metabolism insights" research budget, but with a mass-spectrometry-based metabolomics approach rather than METAFORA's cytometry/RBD approach.

TypeEmerging player
Description

Targeted metabolomics company offering standardized kits and services for metabolic phenotyping. Comparable to METAFORA in targeting metabolism-focused research customers, though using mass-spec assays rather than cytometry and serving a broader metabolite panel than METAFORA's transporter-focused approach.

TypeEmerging player
Description

Biomarker assay and immunoassay platform provider serving pharma, clinical, and research customers. Comparable to METAFORA in offering a specialty biomarker platform (METAglut1/MSD assays target metabolic biomarkers in similar customer accounts) and competing for similar diagnostic and translational research budgets.

TypeEmerging player
Description

Microfluidic cell-sorting and cytometry company targeting research and cell therapy workflows. Comparable to METAFORA as a smaller, niche cytometry platform competing for similar research-customer adoption, though focused on cell sorting rather than metabolism profiling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

METAFORA biosystems

AI-Powered Cytometry and Cell Metabolism Diagnosticsmetafora-biosystems.com

METAFORA biosystems is a French biotech that uses proprietary RBD ligands of nutrient transporters to power METAflow, an AI-enabled cytometry platform for cell metabolism research, and METAglut1™, a diagnostic for Glut1 Deficiency Syndrome, sold to research and clinical institutions.

What METAFORA biosystems does

METAFORA biosystems is a France-headquartered biotechnology company developing proprietary Receptor Binding Domain (RBD) ligands — described as innovative, unmatched ligands of nutrient transporters — and applying them to two product lines. Its core research-use platform, METAflow, delivers AI-powered cytometry and cell metabolism profiling for researchers analyzing cellular metabolic data, while METAglut1™ is a clinical diagnostic and monitoring tool for Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS). Both products are anchored on the same underlying chemistry: RBD ligands that bind specific nutrient transporters and report on cellular metabolic state through cytometry readouts enhanced by machine learning-based predictive analytics.

The company operates commercially through a direct, digital-first go-to-market: it sells via its corporate website with a "BUY NOW" option for kits and provides access to METAflow through a dedicated online portal (eu.metaflow.bio / v2.metaflow.bio), and characterizes its revenue model as subscription/recurring. Customer acquisition leans on scientific publications, webinars, and conference participation aimed at healthcare and research institutions in Western Europe and North America. METAFORA biosystems is a privately held firm founded in 2011, with its registered headquarters at the Pépinière Paris Biotech Santé incubator in Paris (29 rue du Faubourg Saint Jacques) and a US subsidiary, METAFORA biosystems, Inc., in Chicago, Illinois.

METAFORA's funding history is exclusively non-dilutive to date: an early EISMEA grant in 2017, a Horizon 2020 award of approximately $3.8M in 2018, and a European Innovation Council round of approximately $2.6M in 2022, bringing cumulative disclosed funding to roughly $6.4M. Leadership consists of co-founder Vincent Petit (CEO) and co-founder Luc d'Auriol (Chairman). The firm employs between 11 and 50 people, has no disclosed patents, partnerships, named customers, or revenue figures in the source data, and currently markets no standalone AI models, SDKs, or APIs beyond its platform portal.

METAFORA biosystems firmographics

Firmographics
Name
METAFORA biosystems
Legal name
METAFORA biosystems
Website
https://metafora-biosystems.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
METAFORA biosystems is a French biotech that uses proprietary RBD ligands of nutrient transporters to power METAflow, an AI-enabled cytometry platform for cell metabolism research, and METAglut1™, a diagnostic for Glut1 Deficiency Syndrome, sold to research and clinical institutions.
Ownership category
akta.pro rank

METAFORA biosystems industry classification

Industry
Product category
AI-Powered Cytometry and Cell Metabolism Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Cell metabolism profiling
  • AI-powered cytometry
  • Metabolic disorder diagnostics
  • Flow cytometry platform
  • Nutrient transporter ligands

Where METAFORA biosystems is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

METAFORA biosystems business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Products and Platform Services: Revenue generated from sale of METAglut1 diagnostic products and METAflow platform access

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

METAFORA biosystems product offering

Product offering

Core offering

METAFORA biosystems develops and commercializes AI-powered cytometry and cell metabolism profiling tools built on proprietary RBD ligands of nutrient transporters. Its portfolio includes METAflow, a research-oriented cytometry platform for cell metabolism analysis, and METAglut1™, a clinical diagnostic and monitoring solution for Glut1 Deficiency Syndrome (Glut1DS). Both offerings target healthcare and research institutions globally.

Product overview

METAFORA biosystems offers a dual-product portfolio focused on AI-powered cell metabolism analysis. The core offerings include METAflow, an AI-powered cytometry and cell metabolism profiling platform, and METAglut1™, a diagnostic tool for Glut1 deficiency syndrome. Both products leverage artificial intelligence to analyze cellular metabolic data for research and clinical applications.

Differentiator

Problem solved

Functional benefit

Brands

  • METAflow: Flow cytometry platform for AI-powered cell metabolism analysis.
  • METAglut1™

Products and services

  • METAflow METAflow is an AI-powered cytometry and cell metabolism profiling platform that enables researchers and clinical users to analyze cellular metabolic data at single-cell resolution using proprietary RBD ligands of nutrient transporters.
  • METAglut1™ METAglut1™ is a medical diagnostic and monitoring tool for Glut1 Deficiency Syndrome (Glut1DS) that measures glucose transporter 1 deficiency through cell metabolism analysis using METAFORA's proprietary RBD ligand technology.

Companies that use METAFORA biosystems

Customer profile

Segments1 record

Ideal customer profiles1 record

METAFORA biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

METAFORA biosystems partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights5 records

METAFORA biosystems competitors and assessment

Company assessment

Broad incumbents

  • Beckman Coulter Life Sciences: Major flow cytometry and cell analysis incumbent (part of Danaher). Comparable to METAFORA because it serves the same research and clinical cytometry market, but with vastly broader instrument portfolios and a hardware-led model rather than METAFORA's niche metabolism-profiling AI software angle.
  • BD Biosciences: Division of Becton Dickinson and a leading flow cytometry, cell sorting, and reagent provider. Comparable to METAFORA as a flow-cytometry platform competitor targeting similar research and clinical customers, with far greater scale and a broad instrument-plus-reagent portfolio.
  • 10x Genomics: Single-cell and spatial omics platform company serving biomedical researchers. Comparable to METAFORA because researchers evaluating METAflow for cell metabolism profiling are often the same buyers evaluating 10x's single-cell solutions, putting them in overlapping purchasing conversations at research institutions.
  • Thermo Fisher Scientific (Cell Analysis): Diversified life sciences tools giant with a deep cell-analysis portfolio (Attune, flow cytometers, reagents). Comparable as a competing supplier of flow cytometry instruments, reagents, and software to the same healthcare and research institutions METAFORA targets.

Direct peers

  • Cytek Biosciences: Specialist flow cytometry instrumentation company whose spectral cell analyzers compete for the same research-customer budgets as METAFORA's METAflow platform. Highly comparable in core technology (flow cytometry) and customer base (research institutions), though Cytek is focused on hardware while METAFORA is focused on AI-driven metabolism profiling.
  • Standard BioTools (formerly Fluidigm): Provider of mass cytometry (CyTOF) and single-cell analysis instruments used in immunology and cell metabolism research. Comparable to METAFORA because it targets the same research-customer need — deep cellular phenotyping — using cytometry-based instrumentation.

Emerging players

  • Metabolon: Metabolomics services and biomarker discovery company serving pharma and research customers. Comparable to METAFORA because it competes for the same "cell metabolism insights" research budget, but with a mass-spectrometry-based metabolomics approach rather than METAFORA's cytometry/RBD approach.
  • Biocrates Life Sciences: Targeted metabolomics company offering standardized kits and services for metabolic phenotyping. Comparable to METAFORA in targeting metabolism-focused research customers, though using mass-spec assays rather than cytometry and serving a broader metabolite panel than METAFORA's transporter-focused approach.
  • Meso Scale Diagnostics: Biomarker assay and immunoassay platform provider serving pharma, clinical, and research customers. Comparable to METAFORA in offering a specialty biomarker platform (METAglut1/MSD assays target metabolic biomarkers in similar customer accounts) and competing for similar diagnostic and translational research budgets.
  • NanoCellect Biomedical: Microfluidic cell-sorting and cytometry company targeting research and cell therapy workflows. Comparable to METAFORA as a smaller, niche cytometry platform competing for similar research-customer adoption, though focused on cell sorting rather than metabolism profiling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

METAFORA biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

METAFORA biosystems leadership team

Management profile

Number of profiles

Profiles2 records

METAFORA biosystems funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

METAFORA biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about METAFORA biosystems

What does METAFORA biosystems do?

METAFORA biosystems develops and commercializes AI-powered cytometry and cell metabolism profiling tools built on proprietary RBD ligands of nutrient transporters. Its portfolio includes METAflow, a research-oriented cytometry platform for cell metabolism analysis, and METAglut1™, a clinical diagnostic and monitoring solution for Glut1 Deficiency Syndrome (Glut1DS). Both offerings target healthcare and research institutions globally.

Is METAFORA biosystems a public or private company?

METAFORA biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was METAFORA biosystems founded?

METAFORA biosystems was founded in 2011. It employs 11 to 50 people.

Where is METAFORA biosystems based?

METAFORA biosystems is headquartered in Paris, France, in the Europe region.

How does METAFORA biosystems make money?

One revenue line is on record: diagnostic Products and Platform Services.

Who are METAFORA biosystems's main competitors?

Broad incumbents on record are Beckman Coulter Life Sciences, BD Biosciences, 10x Genomics and Thermo Fisher Scientific (Cell Analysis). Direct peers are Cytek Biosciences and Standard BioTools (formerly Fluidigm). Emerging players are Metabolon, Biocrates Life Sciences, Meso Scale Diagnostics and NanoCellect Biomedical.

Does METAFORA biosystems have an API?

No public API is recorded for METAFORA biosystems.

What industry is METAFORA biosystems in?

METAFORA biosystems's product category is AI-Powered Cytometry and Cell Metabolism Diagnostics. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comMETAFORA BIOSYSTEMS SECURES REIMBURSEMENT IN FRANCE FOR FIRST IVD TO HELP DIAGNOSE GLUT1 DEFICIENCY SYNDROMEMetafora Biosystems secured French national health insurance reimbursement for its METAglut1 test for Glut1 deficiency syndrome on February 22, 2024. The test showed 80% sensitivity and 100% specificity in a multicenter study, identifying patients within 48 hours of a blood test. New assays for oncology are under development.BioSpaceMETAFORA Launches METAflow, its Digital Cytometry Analysis PlatformMETAFORA biosystems has launched METAflow, its digital flow cytometry analysis platform, into the Research Use Only (RUO) market with an initial rollout in Europe and the U.S. The cloud-based software utilizes unsupervised algorithms to automate data clustering, aiming to replace manual gating methods for improved efficiency and objectivity. This limited launch serves as a precursor to a global release expected in spring, during which Metafora will also open a U.S. office.Business Wire BlogMETAFORA Launches METAflow, its Digital Cytometry Analysis PlatformMETAFORA biosystems launched METAflow, a cloud-based flow cytometry data analysis platform, into the RUO market. A limited number of licensees from Europe and the U.S. will use it, with feedback guiding a global rollout in spring. The company is also developing a clinical-grade version.Business Wire BlogMETAFORA launches METAflow, a first-in-kind digital cytometry analysis platformMETAFORA biosystems launched METAflow, a cloud-based software for automated multidimensional clustering of flow cytometry data. The beta version received praise in testing, and the company plans to roll it out to the wider research community. A clinical-grade version is next, with a European launch of its first diagnostic test in 2022.PR NewswireSebia and Metafora biosystems form Strategic partnership to Develop Advanced In Vitro Diagnostics testsSebia and Metafora biosystems announced a strategic partnership to develop in-vitro diagnostics, with Sebia acquiring a minority stake in Metafora. The partnership focuses on hematology and oncology, targeting multiple myeloma and metabolic diseases. Metafora plans to launch its first diagnostic test in Europe in 2022.FinSMEsMetafora biosystems Receives €3.2M from EC's H2020 SME Instrument ProgramMetafora biosystems received a €3.2M grant from the European Commission's H2020 SME Instrument program. The funds will accelerate clinical and regulatory development, including a prospective validation study of its METAglut1 test for De Vivo disease, expected to be published in early 2021. The company also plans regulatory proceedings in Europe and the US.